Open AccessAn updated Review on Therapeutic Potential of Entrectinib as a Promising TrK, ROS 1, and ALK Inhibitor in Solid Tumors and Lung Cancer
Author(s) -
M.V. Archana,
Mariya Palathingal,
D. Kannan,
P. Ashisha,
Akash Marathakam Nuaman
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i44a32633
Subject(s) - anaplastic lymphoma kinase , trk receptor , medicine , cancer research , cancer , lung cancer , tyrosine kinase , ros1 , kinase , receptor tyrosine kinase , crizotinib , targeted therapy , oncology , receptor , biology , adenocarcinoma , malignant pleural effusion , neurotrophin , microbiology and biotechnology
Entrectinib is a selective inhibitor of tyrosine kinases , tropomyosin receptor kinases that targets oncogenic rearrangements in Neurotropic Tyrosine Receptor kinase, c-ros oncogene 1 and Anaplastic lymphoma kinase used for the treatment of various solid tumors. Entrectinib gained its first worldwide approval in Japan in June 2019 for the treatment of NTRK fusion-positive, advanced or recurring solid tumours in adults and children. In august 15, 2019 drug got FDA approval for the treatment of solid tumors in adult and children aged 12 and above. This article summarizes current status of Entrectinib from ongoing clinical trails and ideal place for drug in therapy.